Recurrent ALK-Positive Large B-Cell Lymphoma Clinical Trials in La Crosse, Wisconsin

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy